Archive: March 2018

Are Direct Acting Oral Anticoagulants Ready for Prime-Time Use in Cancer-Related Thrombosis?

Michael Blake Streiff, MD

  H&O  How common is thrombosis in patients being treated for cancer? MS  Approximately 20% to 25% of patients with venous thromboembolism (VTE) at a typical […]

Emerging Options for Combination Therapy in Multiple Myeloma

Adriana C. Rossi, MD

  H&O  How has the diagnosis of multiple myeloma evolved? AR  Previously, the definition of active disease required the presence of myeloma cells, an M spike, […]

Update on Hairy Cell Leukemia

Robert J. Kreitman, MD, and Evgeny Arons, PhD

  Abstract:  Hairy cell leukemia (HCL) is a chronic B-cell malignancy with multiple treatment options, including several that are investigational. Patients present with pancytopenia and splenomegaly, […]

Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia in Adults: Current Treatments and Future Perspectives

Musa Yilmaz, MD, Hagop Kantarjian, MD, Farhad Ravandi-Kashani, MD, Nicholas J. Short, MD, and Elias Jabbour, MD

  Abstract: Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) accounts for approximately one-fourth of cases of adult ALL. It typically presents with an aggressive clinical course, […]

The Timing of Molecular Imaging in Prostate Cancer

Michael J. Morris, MD

  H&O  What molecular imaging techniques are available for use in prostate cancer? MM  The US Food and Drug Administration (FDA) has approved 2 tracers for […]

Cost-Effectiveness in the Surgical Care of Renal Cell Carcinoma

From the 16th International Kidney Cancer Symposium November 3-4, 2017, Miami, Florida When it comes to the surgical care of patients with kidney cancer, more is […]

Letter From the Editor: Trivia Night

Brad S. Kahl, MD

Last night, my wife and I went to a fund-raiser for our local elementary school. The school, called North Glendale, is everything a public school should […]

Back to Archive